Clinical Trial Update: An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

An open-label Phase 2 trial comparing trametinib (GSK1120212) with docetaxel in stage IV KRAS-mutant non-small cell lung cancer. The study has completed and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MEKINIST (trametinib)
• Taxotere (docetaxel)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Non-Small Cell | Phase 2 | Status: COMPLETED | Results posted: 2014-05-26